



NATCO PHARMA LIMITED

Statement of stand-alone Financial Results for the quarter and year ended 31st March, 2016

Rs. in lakhs

PART I : STATEMENT OF STAND-ALONE FINANCIAL RESULTS PARTICULARS	THREE MONTHS ENDED			YEAR ENDED	
	(AUDITED)	(UN-AUDITED)		(AUDITED)	
	31 March 2016	31 December 2015	31 March 2015	31 March 2016	31 March 2015
<b>01. INCOME FROM OPERATIONS</b>					
a) Net Sales/Income from Operations (Net of Excise Duty & Sales Tax)	35,731	23,402	16,562	96,816	66,450
b) Other Operating Income	2,034	1,124	1,023	5,327	5,107
<b>TOTAL INCOME FROM OPERATIONS</b>	<b>37,765</b>	<b>24,526</b>	<b>17,585</b>	<b>1,02,143</b>	<b>71,557</b>
<b>02. EXPENDITURE</b>					
a) Cost of materials consumed	10,762	7,912	5,265	30,367	17,858
b) Purchases of stock-in-trade	5	-	88	42	88
c) Changes in inventories of finished goods, work-in progress and stock-in-trade	(998)	(852)	(1,880)	(4,780)	(876)
d) Employee benefits expense	5,165	4,162	3,202	16,905	11,619
e) Depreciation and amortization expense	1,203	1,170	1,129	5,016	4,246
f) Other Expenses	13,609	6,788	4,985	31,859	20,010
<b>TOTAL EXPENSES</b>	<b>29,746</b>	<b>19,180</b>	<b>12,789</b>	<b>79,409</b>	<b>52,945</b>
<b>03. Profit/(Loss) from Operations before other income, finance costs and exceptional items</b>	<b>8,019</b>	<b>5,346</b>	<b>4,796</b>	<b>22,734</b>	<b>18,612</b>
04. Other Income	162	640	255	1,407	1,355
<b>05. Profit/(Loss) from ordinary activities before finance Cost and exceptional items</b>	<b>8,181</b>	<b>5,986</b>	<b>5,051</b>	<b>24,141</b>	<b>19,967</b>
06. Finance costs	331	332	867	2,194	3,013
<b>07. Profit/(Loss) from ordinary activities after finance Costs but before exceptional items</b>	<b>7,850</b>	<b>5,654</b>	<b>4,184</b>	<b>21,947</b>	<b>16,954</b>
08. Exceptional Item	-	-	-	-	1,513
<b>09. Profit/(Loss) from ordinary activities before tax</b>	<b>7,850</b>	<b>5,654</b>	<b>4,184</b>	<b>21,947</b>	<b>15,441</b>
10a. Current Tax expense	1,364	1,206	777	4,480	3,252
10b. Deferred Tax expense/(reversal)	(245)	94	(3,103)	21	(3,103)
<b>11. Net Profit/(Loss) from ordinary activities after tax</b>	<b>6,731</b>	<b>4,354</b>	<b>6,510</b>	<b>17,446</b>	<b>15,292</b>
12. Extraordinary items (net of tax expenses)	-	-	-	-	-
<b>13. Net Profit/(Loss) for the period</b>	<b>6,731</b>	<b>4,354</b>	<b>6,510</b>	<b>17,446</b>	<b>15,292</b>
14. Paid-up Equity Share Capital ( face value of Rs.2/- per equity share)	3,483	3,483	3,323	3,483	3,323
15. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year	-	-	-	1,30,057	84,576
<b>16. Earnings per share (each share of Rs.2/-face value)</b>					
Basic EPS before and after extraordinary item (Rs.) – not-annualized	3.86	2.50	3.93	10.24	9.23
Diluted EPS before and after extraordinary item (Rs.) – not-annualized	3.85	2.49	3.93	10.20	9.23

Dated at Hyderabad, this, the 26th day of May, 2016.  
for and on behalf of the Board of Directors,  
NATCO Pharma Limited

V.C. Nannapaneni  
Chairman & Managing Director



NATCO PHARMA LIMITED

STATEMENT OF STAND-ALONE ASSETS AND LIABILITIES

Rs. In lakhs

Particulars	As at 31-Mar-2016 (Audited)	As at 31-Mar-2015 (Audited)
<b>Equity &amp; Liabilities</b>		
<b>Shareholders' Funds</b>		
a) Share Capital	3,483	3,323
b) Reserves & Surplus	1,30,057	84,576
<b>Sub-total: Shareholders' Funds</b>	<b>1,33,540</b>	<b>87,899</b>
<b>Non-current liabilities</b>		
a) Long term borrowings	-	9,628
b) Deferred tax liabilities(net)	1,442	1,129
c) Other long-term liabilities	77	77
d) Long term provisions	1,247	919
<b>Sub-total: Non-current Liabilities</b>	<b>2,766</b>	<b>11,753</b>
<b>Current Liabilities</b>		
a) Short term borrowings	9,603	16,854
b) Trade payables :Due to micro and small enterprises	27,007	11,534
c) Other current liabilities	11,081	11,332
d) Short-term provisions	145	111
<b>Sub-total: Current Liabilities</b>	<b>47,836</b>	<b>39,831</b>
<b>TOTAL- EQUITY AND LIABILITIES</b>	<b>1,84,142</b>	<b>1,39,483</b>
<b>Assets</b>		
<b>Non-Current Assets</b>		
a) Fixed Assets		
Tangible Assets	70,035	56,802
Intangible Assets	525	471
b) Capital Work-in-progress	21,181	10,077
c) Non- Current Investments	7,167	13,115
d) Long term loans and advances	6,181	14,247
e) Other non-current assets	422	352
<b>Sub-total: Non-Current Assets</b>	<b>1,05,511</b>	<b>95,064</b>
<b>Current Assets</b>		
a) Current Investments	2,096	12
b) Inventories	35,191	19,835
c) Trade receivables	25,584	18,896
d) Cash and Cash Equivalents	4,017	719
e) Short term loans and advances	10,241	4,766
f) Other Current Assets	1,502	191
<b>Sub-total: Current Assets</b>	<b>78,631</b>	<b>44,419</b>
<b>TOTAL- ASSETS</b>	<b>1,84,142</b>	<b>1,39,483</b>



NATCO PHARMA LIMITED

Statement of stand-alone segment wise revenue, results and capital employed for the quarter and year ended on 31st March, 2016

Rs. In lakhs

PARTICULARS	THREE MONTHS ENDED			AUDITED STANDALONE	
	(AUDITED) 31-Mar-16	(UN-AUDITED) 31-Dec-15	(UN-AUDITED) 31-Mar-15	Year Ended 31-Mar-16	Year Ended 31-Mar-15
<b>01. Segment Revenue(Net)</b>					
a) Bulk Chemicals	9,179	6,773	7,171	26,972	29,468
b) Formulations	33,392	20,261	11,943	83,709	42,524
c) Job Work	172	149	218	669	830
d) Unallocated	34	132	504	523	2,502
<b>Total</b>	<b>42,777</b>	<b>27,315</b>	<b>19,836</b>	<b>1,11,874</b>	<b>75,324</b>
Less: Inter-Segment Revenue	5,012	2,789	2,251	9,731	3,767
<b>Net Sales/Income from Operations</b>	<b>37,765</b>	<b>24,526</b>	<b>17,585</b>	<b>1,02,142</b>	<b>71,557</b>
<b>02. Segment Results: Profit(+)/Loss(-) before tax and interest</b>					
a) Bulk Chemicals	2,388	433	2,593	3,930	8,043
b) Formulations	11,606	8,256	4,159	32,355	17,784
c) Job Work	164	137	179	599	684
d) Unallocated	118	43	673	481	1,354
<b>Total</b>	<b>14,276</b>	<b>8,869</b>	<b>7,604</b>	<b>37,364</b>	<b>27,865</b>
Less: a) Interest	48	332	867	2,194	3,013
b) Other unallocable expenditure	6,672	3,523	2,807	14,631	10,766
c) Unallocable Income	(294)	(640)	(255)	(1,407)	(1,355)
<b>Total Profit Before Tax</b>	<b>7,850</b>	<b>5,654</b>	<b>4,185</b>	<b>21,947</b>	<b>15,441</b>
<b>03. Capital Employed (Segment Assets - Segment Liabilities)</b>					
a) Bulk Chemicals	54,720	48,829	44,091	54,720	44,091
b) Formulations	53,157	50,586	44,740	53,157	44,740
c) Job Work	275	128	227	275	227
d) Unallocated	25,388	33,572	(1,159)	25,388	(1,159)
<b>Total</b>	<b>1,33,540</b>	<b>1,33,115</b>	<b>87,899</b>	<b>1,33,540</b>	<b>87,899</b>

The above un-audited stand-alone financial results were reviewed by the Audit Committee and approved by the Board of Directors at a meeting held on 26 May 2016 at Hyderabad.

**Notes:**

1. Equity shares of the Company with face value of Rs.10 per share were sub-divided into 5 equity shares of Rs.2 each effective 30 November 2015. Consequently, in accordance with Accounting Standard (AS) 20 - "Earnings Per Share", the basic and diluted earnings per share of the previous periods have been recomputed and disclosed accordingly.

2. NATCO Organics Limited ("NOL"), a wholly owned subsidiary of the Company, amalgamated with the Company, with effect from 1 April 2015 ("the appointed date"). The amalgamation was pursuant to a composite scheme of amalgamation sanctioned by the Honourable High Court of Judicature at Madras vide their Order dated 28 April 2016. Pursuant thereto all the assets and properties, both movable and immovable, rights, title and interests, secured and unsecured debts, borrowings, and all other duties, debts, liabilities, undertakings and obligations of NOL, have been transferred to and vested in the Company retrospectively with effect from 1 April 2015. The amalgamation has been accounted for under the 'pooling of interests' method as prescribed by Accounting Standard 14 specified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014. Accordingly, the assets, liabilities and reserves of NATCO Organics Limited as at 1 April 2015 have been taken over at their book values and in the same form. Pursuant to the above, the standalone financial results for the quarter ended 31 March 2016 together with the standalone financial results for the nine months period ended 31 December 2015 as published by the Company are not comparable with the standalone financial results for the financial year ended 31 March 2016 due to the effect of the aforesaid amalgamation.

3. Exceptional item for the year ended 31 March 2015, represents amount paid and accounted against settlement of pending legal dispute Rs.1513/- lakhs.

4. On the basis of management's assessment of its future business plan and the impact thereof on the future taxable income, the management believes that the Company would continue to pay tax on income under the Minimum Alternate Tax (MAT) provisions of the Income Tax Act, 1961 over the next several years. Thus, deferred tax liabilities (net) aggregating to Rs.3103/- lakhs recognized in the earlier years on the timing differences which is expected to be reversed during the MAT period is de-recognized during the quarter ended 31 March 2015 in accordance with the provisions of Accounting Standard 22 - 'Accounting for Taxes on Income'.

5. Figures for the quarter ended on 31st March are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the financial year.

6. The Company has allotted 1,600,000 equity shares of Rs.10 each at a premium of Rs.2,120.55 per equity share on 18 September 2015 pursuant to a Qualified Institutions Placement under Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 (as amended). Share issue expenses amounting to Rs.642 lakhs have been adjusted against the Securities Premium Account in terms of the provisions of Section 52 of the Companies Act, 2013.
7. The Board of directors have recommended an interim dividend of Rs.1.25 per equity share of Rs.2 each.
8. As at 31 March 2016, short term loans and advances includes term deposit with financial institutions amounting to Rs. 4,000lakhs.
9. Figures for the previous period(s) have been re-arranged / re-grouped wherever necessary.

Dated at Hyderabad, this, the 26th day of May, 2016.  
for and on behalf of the Board of Directors,  
NATCO Pharma Limited



V.C. Nannapaneni  
Chairman & Managing Director

---

Regd. Office: NATCO House, Road # 2, Banjara Hills, Hyderabad : 500 034



NATCO PHARMA LIMITED

Statement of consolidated Financial Results for the quarter and year ended 31st March, 2016

Rs.in lakhs

PART I : STATEMENT OF CONSOLIDATED RESULTS PARTICULARS	THREE MONTHS ENDED			YEAR ENDED	
	(AUDITED)	(UN-AUDITED)		(AUDITED)	
	31 March 2016	31 December 2015	31 March 2015	31 March 2016	31 March 2015
<b>01. INCOME FROM OPERATIONS</b>					
a) Net Sales/Income from Operations (Net of Excise Duty & Sales Tax)	38,677	26,312	19,057	1,08,835	77,420
b) Other Operating Income	2,020	1,292	1,023	5,327	5,107
<b>TOTAL INCOME FROM OPERATIONS</b>	<b>40,697</b>	<b>27,604</b>	<b>20,080</b>	<b>1,14,162</b>	<b>82,527</b>
<b>02. EXPENDITURE</b>					
a) Cost of materials consumed	10,734	7,649	6,872	30,367	16,726
b) Purchases of stock-in-trade	1,868	2,340	-	8,911	8,428
c) Changes in inventories of finished goods, work-in progress and stock-in-trade	(1,425)	(774)	(1,921)	(5,166)	(917)
d) Employee benefits expense	5,643	4,695	3,838	18,668	13,692
e) Depreciation and amortization expense	1,231	1,332	1,280	5,095	4,726
f) Other Expenses	14,626	7,567	6,345	34,409	23,261
<b>TOTAL EXPENSES</b>	<b>32,677</b>	<b>22,809</b>	<b>16,414</b>	<b>92,284</b>	<b>65,916</b>
<b>03. Profit/(Loss) from Operations before other income, finance costs and exceptional items</b>	<b>8,020</b>	<b>4,795</b>	<b>3,666</b>	<b>21,878</b>	<b>16,611</b>
04. Other Income	150	536	320	1,076	1,491
<b>05. Profit/(Loss) from ordinary activities before finance Cost and exceptional items</b>	<b>8,170</b>	<b>5,331</b>	<b>3,986</b>	<b>22,954</b>	<b>18,102</b>
06. Finance costs	358	358	937	2,290	3,168
<b>07. Profit/(Loss) from ordinary activities after finance Costs but before exceptional items</b>	<b>7,812</b>	<b>4,973</b>	<b>3,049</b>	<b>20,664</b>	<b>14,934</b>
08. Exceptional Item	-	-	-	-	1,513
<b>09. Profit/(Loss) from operations before tax</b>	<b>7,812</b>	<b>4,973</b>	<b>3,049</b>	<b>20,664</b>	<b>13,421</b>
10a. Current Tax expense	1,783	1,212	851	5,030	3,512
10b. Deferred Tax expense /(reversal)	(16)	94	(3,117)	250	(3,117)
<b>11. Net Profit/ (Loss) from ordinary activities after tax</b>	<b>6,045</b>	<b>3,667</b>	<b>5,315</b>	<b>15,384</b>	<b>13,026</b>
<b>11g. Profit after tax and before minority interest</b>	<b>6,045</b>	<b>3,667</b>	<b>5,315</b>	<b>15,384</b>	<b>13,026</b>
12. Minority Interest	21	(48)	(129)	(135)	(435)
<b>13. Net Profit/ (Loss) for the period</b>	<b>6,024</b>	<b>3,715</b>	<b>5,444</b>	<b>15,519</b>	<b>13,461</b>
13a. Net Profit/(Loss) from continuing operations	6,082	-	-	15,300	13,461
13b. Net Profit/(Loss) from discontinuing operations	(58)	-	-	219	-
14. Paid-up Equity Share Capital (each share of Rs.2/-face value)	3,483	3,483	3,323	3,483	3,323
15. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year	-	-	-	1,26,350	81,282
<b>16. Earnings per share (each share of Rs.2/-face value)</b>					
Basic EPS before and after extraordinary item (Rs.) – not-annualized	3.46	2.13	3.28	9.10	8.13
Diluted EPS before and after extraordinary item (Rs.) – not-annualized	3.45	2.13	3.28	9.08	8.13

The un-audited consolidated financial results were reviewed by the Audit Committee, and approved by the Board of Directors at a meeting held at Hyderabad, on Thursday, the 26th May, 2016.

There are no exceptional and extraordinary items to be reported for the period under review.

The stand alone result are available on the company website [www.natcopharma.co.in](http://www.natcopharma.co.in).

Dated at Hyderabad, this, the 26th day of May, 2016.

for and on behalf of the Board of Directors,  
NATCO Pharma Limited

V.C. Nannapaneni  
Chairman & Managing Director



NATCO PHARMA LIMITED

STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES

Rs. In Lakhs

Particulars	As at 31-Mar-2016 (Audited)	As at 31-Mar-2015 (Audited)
<b>Equity and Liabilities</b>		
<b>Shareholders' Funds</b>		
a) Share Capital	3,483	3,323
b) Reserves and Surplus	1,26,350	81,282
<b>Sub-total: Shareholders' funds</b>	<b>1,29,833</b>	<b>84,605</b>
c) Minority Interest	491	503
<b>Non-Current Liabilities</b>		
a) Long term borrowings	-	9,702
b) Deferred tax liabilities (net)	1,442	1,189
c) Other long-term liabilities	77	83
d) Long term provisions	1,247	950
<b>Sub-total: Non-current Liabilities</b>	<b>2,766</b>	<b>11,924</b>
<b>Current Liabilities</b>		
a) Short term borrowings	9,836	16,854
b) Trade payables	27,552	12,530
c) Other current liabilities	11,418	11,856
d) Short-term provisions	485	133
<b>Sub-total: Current Liabilities</b>	<b>49,291</b>	<b>41,373</b>
<b>TOTAL- EQUITY AND LIABILITIES</b>	<b>1,82,381</b>	<b>1,38,405</b>
<b>Assets</b>		
<b>Non-Current Assets</b>		
a) Fixed Assets		
Tangible Assets	70,460	66,403
Intangible Assets	892	4,595
b) Capital Work-in-progress	21,181	12,896
c) Non- Current Investments	7	157
d) Long term loans and advances	6,187	5,703
e) Other non-current assets	424	354
<b>Sub-total: Non-Current Assets</b>	<b>99,151</b>	<b>90,108</b>
<b>Current Assets</b>		
a) Current Investments	2,096	12
b) Inventories	35,728	22,000
c) Trade receivables	26,160	19,243
d) Cash and Cash Equivalents	4,512	1,336
e) Short term loans and advances	10,382	5,515
f) Other Current Assets	4,352	191
<b>Sub-total: Current Assets</b>	<b>83,230</b>	<b>48,297</b>
<b>TOTAL- ASSETS</b>	<b>1,82,381</b>	<b>1,38,405</b>